Bexarotene safe treatment for early-stage CTCL


Washington - Bexarotene gel appears to be an effective and well-tolerated monotherapy when used as first-line treatment for early-stage cutaneous T-cell lymphoma, Madeleine Duvic, M.D., reported at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.